Details

Autor(en) / Beteiligte

• Evans, D Gareth
• Woodward, Emma R
• Bajalica-Lagercrantz, Svetlana
• Oliveira, Carla
• Frebourg, Thierry

Titel

Germline TP53 Testing in Breast Cancers: Why, When and How?

Ist Teil von

• Cancers, 2020-12, Vol.12 (12), p.3762

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2020

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Germline variants represent a main genetic cause of breast cancers before 31 years of age. Development of cancer multi-gene panels has resulted in an exponential increase of germline testing in breast cancer patients. Interpretation of variants, which are mostly missense, is complex and requires excluding clonal haematopoiesis and circulating tumour DNA. In breast cancer patients harbouring germline disease-causing variants, radiotherapy contributing to the development of subsequent tumours should be, if possible, avoided and, within families, annual follow-up including whole-body MRI should be offered to carriers. We consider that, in breast cancer patients, germline testing should be performed before treatment and offered systematically only to patients with: (i) invasive breast carcinoma or in situ (DCIS) before 31; or (ii) bilateral or multifocal or HER2+ invasive breast carcinoma/DCIS or phyllode tumour before 36; or (iii) invasive breast carcinoma before 46 and another core tumour (breast cancer, soft-tissue sarcoma, osteosarcoma, central nervous system tumour, adrenocortical carcinoma); or (iv) invasive breast carcinoma before 46 and one first- or second-degree relative with a core tumour before 56. In contrast, women presenting with breast cancer after 46, without suggestive personal or familial history, should not be tested for